Paul Cottu

10.6k total citations · 1 hit paper
233 papers, 5.1k citations indexed

About

Paul Cottu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Paul Cottu has authored 233 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Oncology, 94 papers in Pulmonary and Respiratory Medicine and 88 papers in Cancer Research. Recurrent topics in Paul Cottu's work include Breast Cancer Treatment Studies (64 papers), Advanced Breast Cancer Therapies (58 papers) and HER2/EGFR in Cancer Research (52 papers). Paul Cottu is often cited by papers focused on Breast Cancer Treatment Studies (64 papers), Advanced Breast Cancer Therapies (58 papers) and HER2/EGFR in Cancer Research (52 papers). Paul Cottu collaborates with scholars based in France, United States and Italy. Paul Cottu's co-authors include Jean‐Yves Pierga, Gilles Thomas, Richard C. Hamelin, François‐Clément Bidard, Xavier Sastre‐Garau, Anne Vincent‐Salomon, Jean Marc Extra, Guy Meyer, Zora Marjanovic and Philippe Solal‐Céligny and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Paul Cottu

213 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer

2002 620 citations Paul Cottu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Cottu France	36	2.5k	1.8k	1.3k	1.1k	981	233	5.1k
Marek Z. Wojtukiewicz Poland	34	2.2k 0.9×	939 0.5×	1.0k 0.8×	809 0.7×	342 0.3×	190	4.5k
Gloria Broadwater United States	42	3.1k 1.2×	1.8k 1.0×	1.2k 0.9×	1.0k 0.9×	592 0.6×	182	6.2k
Irene Floriani Italy	47	3.3k 1.3×	874 0.5×	1.2k 0.9×	2.3k 2.1×	1.2k 1.3×	159	8.3k
Giuseppe Colucci Italy	27	2.0k 0.8×	576 0.3×	615 0.5×	1.1k 1.0×	392 0.4×	123	3.7k
Jee Hyun Kim South Korea	43	5.2k 2.0×	1.4k 0.7×	1.5k 1.2×	2.9k 2.6×	705 0.7×	320	8.1k
Guenther G. Steger Austria	34	4.6k 1.8×	1.3k 0.7×	1.3k 1.0×	1.5k 1.3×	342 0.3×	156	6.0k
Sigurd Lax Austria	39	2.1k 0.8×	1.8k 1.0×	1.5k 1.2×	867 0.8×	732 0.7×	145	5.9k
Aaron S. Mansfield United States	40	3.8k 1.5×	669 0.4×	1.2k 1.0×	2.4k 2.1×	320 0.3×	254	6.2k
Roderich E. Schwarz United States	42	2.2k 0.9×	558 0.3×	1.2k 0.9×	2.4k 2.2×	350 0.4×	184	5.7k
Eliana Rulli Italy	33	2.6k 1.0×	687 0.4×	1.1k 0.8×	1.3k 1.2×	767 0.8×	130	4.4k

Countries citing papers authored by Paul Cottu

Since Specialization

Citations

This map shows the geographic impact of Paul Cottu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Cottu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Cottu more than expected).

Fields of papers citing papers by Paul Cottu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Cottu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Cottu. The network helps show where Paul Cottu may publish in the future.

Co-authorship network of co-authors of Paul Cottu

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Cottu. A scholar is included among the top collaborators of Paul Cottu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Cottu. Paul Cottu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Loap, Pierre, et al.. (2025). Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer. American Journal of Clinical Oncology. 48(8). 399–402. 3 indexed citations

Kieffer, Yann, Arianna Mencattini, Rana Mhaidly, et al.. (2025). An Extracellular Matrix–Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation. Cancer Research. 86(4). 1054–1072.

Pérez-García, José Manuel, Meritxell Bellet, Miguel Gil‐Gil, et al.. (2025). Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial. ESMO Open. 10(7). 105309–105309.

Loirat, Delphine, Nicolas Kiavué, Diana Bello Roufai, et al.. (2024). Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 31(4). 572–580. 11 indexed citations

Loap, Pierre, et al.. (2024). Concurrent Use of Radiotherapy and Ribociclib. American Journal of Clinical Oncology. 47(12). 574–579. 2 indexed citations

Sandoval, José Luís, Maria Alice Franzoi, Antonio Di Meglio, et al.. (2024). Magnitude and Temporal Variations of Socioeconomic Inequalities in the Quality of Life After Early Breast Cancer: Results From the Multicentric French CANTO Cohort. Journal of Clinical Oncology. 42(24). 2908–2917. 7 indexed citations

Jourdan, Nathalie, et al.. (2024). Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach. British Journal of Clinical Pharmacology. 90(5). 1333–1343.

Vanacker, Hélène, Isabelle Treilleux, Camille Schiffler, et al.. (2024). p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British Journal of Cancer. 130(4). 613–619.

Licaj, Idlir, Elodie Coquan, Tienhan Sandrine Dabakuyo‐Yonli, et al.. (2023). Baseline quality of life and chemotherapy toxicities in patients with early breast cancer. Cancer. 129(7). 1085–1095. 4 indexed citations

10.

Beddok, Arnaud, et al.. (2023). Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer. International Journal of Cancer. 153(7). 1386–1396. 3 indexed citations

11.

Beddok, Arnaud, et al.. (2023). Aspects biologiques, précliniques et cliniques de l’association de radiothérapie et d’inhibiteur de CDK 4/6. Cancer/Radiothérapie. 27(3). 240–248. 2 indexed citations

12.

Soldato, Davide, Julie Havas, Tracy E. Crane, et al.. (2022). Coffee and tea consumption, patient‐reported, and clinical outcomes in a longitudinal study of patients with breast cancer. Cancer. 128(19). 3552–3563. 3 indexed citations

13.

Benoit, Louise, Roman Rouzier, Paul Cottu, et al.. (2021). Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer. Clinical Breast Cancer. 22(3). e352–e361.

14.

Gbenou, Arnauld, Julie Havas, Élise Martin, et al.. (2021). Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. The Breast. 57. 43–48. 3 indexed citations

15.

Gal, Jocelyn, G. Milano, Patrick Brest, et al.. (2020). VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study. Pharmaceuticals. 13(11). 414–414. 7 indexed citations

16.

Ng, Charlotte K.Y., François‐Clément Bidard, Salvatore Piscuoglio, et al.. (2017). Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. Clinical Cancer Research. 23(15). 4402–4415. 83 indexed citations

17.

Gurard‐Levin, Zachary A., Natalie A. Twine, Véra Pancaldi, et al.. (2016). Chromatin Regulators as a Guide for Cancer Treatment Choice. Molecular Cancer Therapeutics. 15(7). 1768–1777. 15 indexed citations

18.

Cottu, Paul. (2016). Les traitements médicaux néoadjuvants des cancers du sein luminaux en 2016. Bulletin du Cancer. 104(1). 69–78. 4 indexed citations

19.

Cottu, Paul, Ivan Bièche, Franck Assayag, et al.. (2014). Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts. Clinical Cancer Research. 20(16). 4314–4325. 42 indexed citations

20.

Cottu, Paul, et al.. (2001). Residual Tumor Cell Contamination in Peripheral Blood Stem Cells Collections of 117 Breast Cancer Patients Evaluated by Immunocytochemical Technique. Journal of Hematotherapy & Stem Cell Research. 10(6). 855–862. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact